Abstract
Hypertrophic growth is a risk factor for mortality in heart diseases. Mechanisms are lacking for this global increase in RNA and protein per cell, which underlies hypertrophy. Hypertrophic signals cause phosphorylation of the RNA polymerase II C-terminal domain, required for transcript elongation. RNA polymerase II kinases include cyclin-dependent kinases-7 (Cdk7) and Cdk9, components of two basal transcription factors. We report activation of Cdk7 and -9 in hypertrophy triggered by signaling proteins (Gαq, calcineurin) or chronic mechanical stress. Only Cdk9 was activated by acute load or, in culture, by endothelin. A preferential role for Cdk9 was shown in RNA polymerase II phosphorylation and growth induced by endothelin, using pharmacological and dominant-negative inhibitors. All four hypertrophic signals dissociated 7SK small nuclear RNA, an endogenous inhibitor, from cyclin T–Cdk9. Cdk9 was limiting for cardiac growth, shown by suppressing its inhibitor (7SK) in culture and preventing downregulation of its activator (cyclin T1) in mouse myocardium.
Note: In the AOP version of this article, the numbering of the author affiliations was incorrect. This has now been fixed, and the affiliations appear correctly online and in print.
This is a preview of subscription content, access via your institution
Access options
Similar content being viewed by others
Change history
16 October 2002
This was incorrect in AOP version but corrected in print. Renumbered the affiliations and added one line in the acknowledgments, as per the note.
References
Sadoshima, J. & Izumo, S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 59, 551–571 (1997).
MacLellan, W.R. & Schneider, M.D. Genetic dissection of cardiac growth control pathways. Annu. Rev. Physiol. 62, 289–320 (2000).
Verdecchia, P. et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J. Am. Coll. Cardiol. 38, 1829–1835 (2001).
Mathew, J. et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104, 1615–1621 (2001).
Esposito, G. et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85–92 (2002).
Sano, M. & Schneider, M.D. Still stressed out but doing fine: Normalization of wall stress is superfluous to maintaining cardiac function in chronic pressure overload. Circulation 105, 8–10 (2002).
McKinsey, T.A. & Olson, E.N. Cardiac hypertrophy: sorting out the circuitry. Curr. Opin. Genet. Develop. 9, 267–274 (1999).
Molkentin, J.D. & Dorn, G.W., 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391–426 (2001).
Molkentin, J.D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998).
Adams, J.W. et al. Enhanced Gαq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl. Acad. Sci. USA 95, 10140–10145 (1998).
Zhang, D. et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6, 556–563 (2000).
Shioi, T. et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537–2548 (2000).
Bueno, O.F. et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341–6350 (2000).
Minamino, T. et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc. Natl. Acad. Sci. USA 99, 3866–3871 (2002).
Antos, C.L. et al. Activated glycogen synthase-3 β suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 99, 907–912 (2002).
Oh, H. et al. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc. Natl. Acad. Sci. USA 98, 10308–10313 (2001).
Shioi, T. et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22, 2799–2809. (2002).
Dahmus, M.E. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J. Biol. Chem. 271, 19009–19012 (1996).
Akhtar, A., Faye, G. & Bentley, D.L. Distinct activated and non-activated RNA polymerase II complexes in yeast. EMBO J. 15, 4654–4664. (1996).
Cho, H. et al. A protein phosphatase functions to recycle RNA polymerase II. Genes Dev. 13, 1540–1552 (1999).
Orphanides, G. & Reinberg, D. A unified theory of gene expression. Cell 108, 439–451 (2002).
Majello, B. & Napolitano, G. Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. Front. Biosci. 6, D1358–1368 (2001).
Abdellatif, M. et al. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: Implications for cardiac hypertrophy. Mol. Cell. Biol. 18, 6729–6736 (1998).
De Luca, A. et al. Cyclin T2a gene maps on human chromosome 2q21. J. Histochem. Cytochem. 49, 693–698 (2001).
Kwak, Y.T., Ivanov, D., Guo, J., Nee, E. & Gaynor, R.B. Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. J. Mol. Biol. 288, 57–69 (1999).
Wimmer, J. et al. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology 255, 182–189 (1999).
Peng, J., Zhu, Y., Milton, J.T. & Price, D.H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12, 755–762 (1998).
Dorn, G.W. & Brown, J.H. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc. Med. 9, 26–34 (1999).
Doi, T., Sugimoto, H., Arimoto, I., Hiroaki, Y. & Fujiyoshi, Y. Interactions of endothelin receptor subtypes A and B with Gi, Go, and Gq in reconstituted phospholipid vesicles. Biochemistry 38, 3090–3099 (1999).
Taigen, T., De Windt, L.J., Lim, H.W. & Molkentin, J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA 97, 1196–1201 (2000).
Asakura, M. et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nature Med. 8, 35–40. (2002).
Zhou, M. et al. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol. Cell. Biol. 20, 5077–5086 (2000).
Patturajan, M. et al. Growth-related changes in phosphorylation of yeast RNA polymerase II. J. Biol. Chem. 273, 4689–4694. (1998).
Herrmann, C.H. & Mancini, M.A. The Cdk9 and cyclin T subunits of TAK/P-TEFb localize to splicing factor-rich nuclear speckle regions. J. Cell. Sci. 114, 1491–1503. (2001).
Zhu, Y. et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11, 2622–2632 (1997).
Yang, Z., Zhu, Q., Luo, K. & Zhou, Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 414, 317–322 (2001).
Nguyen, V.T., Kiss, T., Michels, A.A. & Bensaude, O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 414, 322–325 (2001).
Gaussin, V. et al. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc. Natl. Acad. Sci. USA 99, 2878–2883 (2002).
Wada, T. et al. FACT relieves DSIF/NELF-mediated inhibition of transcriptional elongation and reveals functional differences between P-TEFb and TFIIH. Mol. Cell 5, 1067–1072 (2000).
Chao, S.H. & Price, D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276, 31793–31799. (2001).
Yang, X., Herrmann, C.H. & Rice, A.P. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 70, 4576–4584 (1996).
Subramaniam, A. et al. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266, 24613–24620 (1991).
He, T.C. et al. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509–2514 (1998).
Matsuoka, M., Kato, J.Y., Fisher, R.P., Morgan, D.O. & Sherr, C.J. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol. Cell. Biol. 14, 7265–7275 (1994).
de Falco, G. et al. Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. Oncogene 19, 373–379 (2000).
Acknowledgements
We thank B. Boerwinkle, P. Kulkarni, G. Taffett, J. Pocius, L. Shirley & K. Youker for assistance; and R. J. Schwartz, H. Handa, A. Rice, C. Herrmann, W. Harper and L. Wei for helpful discussions. This work was supported in part by National Institutes of Health grants (to M.D.S.), the M.D. Anderson Foundation Professorship (to M.D.S.), the Japan Heart Foundation (to M.S.) and the Bayer Yakuhin Research Grant Abroad (to M.S.). L.B. and A.G. were supported by NIH Grant RO1 CA 60999-01A1 and by SHRO.
Note: In the AOP version of this article, the last sentence in the Acknowledgments section was inadvertantly omitted. This has now been fixed, and the acknowledgments appear correctly online and in print.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.D.S. received research support from Aventis corporation.
Rights and permissions
About this article
Cite this article
Sano, M., Abdellatif, M., Oh, H. et al. Activation and function of cyclin T–Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 8, 1310–1317 (2002). https://doi.org/10.1038/nm778
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm778
This article is cited by
-
Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9
Cardiovascular Drugs and Therapy (2023)
-
A structure-based mechanism for displacement of the HEXIM adapter from 7SK small nuclear RNA
Communications Biology (2022)
-
Change of Heart: the Epitranscriptome of Small Non-coding RNAs in Heart Failure
Current Heart Failure Reports (2022)
-
CDK9 keeps RNA polymerase II on track
Cellular and Molecular Life Sciences (2021)
-
SUMO suppresses and MYC amplifies transcription globally by regulating CDK9 sumoylation
Cell Research (2018)